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RNA interference (RNAi) is an endogenous regulatory pro-
cess whereby double-stranded RNA (dsRNA) present in the
cell cytoplasm causes sequence-specific, post-transcriptional
gene silencing [1]. dsRNA is first cleaved into short (19-21
nucleotides long) dsRNA fragments (siRNA) by Dicer, an
endoribonuclease. The siRNA, which may be endogenous
or exogenous (synthetically produced therapeutic) is subse-
quently loaded onto the RNA-induced silencing complex
(RISC). The sense or passenger strand of the siRNA is then
unwound and cleaved. The retained anti-sense or guide
strand is highly specific to the target messenger RNA
(mRNA) through complementary base paring. The acti-
vated RISC-siRNA complex scans, binds and degrades the
complementary target mRNA present in the cell cytoplasm
at a highly specific position relative to the 5’ end of the anti-
sense strand, thus causing degradation of the complemen-
tary mRNA, which then leads to gene silencing. This
process is catalytic, allowing the same RISC-siRNA complex
to cleave multiple copies of the target mRNAs, and will con-
tinue until the siRNA is degraded or diluted upon cell
division.
With the decoding of the human genome siRNA has
emerged as a broadly applicable and versatile therapeutic
platform. The drug discovery aspect is greatly optimized
for therapeutic siRNA compared to small molecular weight
drugs, as one only requires knowledge of the sequence of
the target gene in the case of siRNA, while trial and error
through more or less random modification of the drug is
required during screening of small drug molecules [2]. The
specificity of siRNA is particularly relevant in the treatment
of cancer, as there is the potential to selectively act only on
cancerous cells, even when the therapeutic reaches non-
target cell populations. siRNA therapy also holds promise
in targeting the so-called ‘non-druggable’ diseases - those
not amenable to conventional therapeutics such as small
molecules, or monoclonal antibodies [3]. Another advan-
tage of therapeutic siRNA is that gene regulation happens
in the cell cytosol, and not the nucleus as in DNA-based
gene therapies. This is significant, as the passive transport
through the nuclear membrane is highly regulated, much
more so than that across the cellular membrane, and is
thus particularly relevant to postmitotic cells such as those
in the airways.
The critical limiting factor in translating siRNA thera-
peutics to the clinic is the ability to efficiently deliver
siRNA to the cell cytoplasm.[4]. Free siRNA is very
unstable in the extracellular milieu, with plasma half-lives
of only ca. 10 min [5] Moreover, due to its negative charge
and large size, free siRNA is not readily internalized
through passive diffusion, and is easily degraded in the
lysosomes following cellular internalization through endo-
cytosis [4,6]. Therefore, only a small fraction of the initial
siRNA dose reaches the cell cytosol when administered as
a free molecule. The use of nanocarriers for the efficient
delivery of siRNA, and the ability to formulate such nano-
carriers for regional delivery to the tissue of interest is
thus of great relevance in developing siRNA therapeutic
platforms.
Because viral carriers are potentially associated with
severe immunological responses, non-viral siRNA carriers
are preferred [6]. Non-viral (nano)carriers may involve
complexation of siRNA with a positively charged carrier,
chemical conjugation, or encapsulation [5,7]. The most
widely used methods for the delivery of nucleic acids are
lipoplexes, and polyplexes, and complexes/self-assembled
domains. Conjugation of siRNA to singly functionalizable
molecules such as PEG and cholesterol has been also
explored. More recently, conjugation of siRNA to multiva-
lent nanocarriers has been proposed, and this strategy may
provide unique opportunities that may help overcome the
challenges associated with the delivery of siRNA with
complexes and singly functionalizable molecules. In this1Wayne State University, Detroit, MI, USA
Full list of author information is available at the end of the article
da Rocha and Conti BMC Proceedings 2014, 8(Suppl 4):O13
http://www.biomedcentral.com/1753-6561/8/S4/O13
© 2014 Rocha and Conti; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
work we will discuss recent advances on the use of nano-
carriers for siRNA delivery, with a special focus on the tar-
geting of lung diseases. We will also discuss strategies for
the formulation of such siRNA carriers for the regional
delivery to the lungs using oral inhalation devices.
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